Get ready to energize your life?
Top Offers Only Today
Support your health and step-up your mental focus
post in: Beauty, Video Date:22 Nov 2017, 18:35 views:2851
Abstract, asthma and chronic obstructive pulmonary disease (copd) are prevalent conditions, and despite recent advances and multiple available therapies and interventions, there remains a significant unmet clinical need. In recent years, it has become clear that there is both significant heterogeneity within each of these conditions and additionally significant overlap in many of the clinical and inflammatory features.
In parallel, useful clinical and immunological biomarkers which inform about prognosis and response to therapy have emerged in both asthma and copd. These biomarkers will allow both better targeting of existing treatments and the identification of those aerosol patients who will respond to novel therapies which are now becoming available. Biomarkers will also facilitate the identification of novel therapeutic targets for future development.
Delivery of precision medicine in airways disease is now feasible and is a core component of a personalised healthcare delivery in asthma and copd. Karger AG, Basel, introduction.
Asthma is a clinical syndrome characterised by variable symptoms of wheeze, breathlessness, chest tightness and cough in association with bronchial hyperresponsiveness and reversible airflow obstruction.
Chronic obstructive pulmonary disease (copd) is similarly characterised by symptoms of wheeze, breathlessness, chest tightness and cough which is usually productive and is associated with fixed airflow limitation, a feature which is included in most definitions.
In addition to chronic symptoms, both asthma and copd are also associated with a tendency to deteriorate in an abrupt or sub-acute manner. These events are usually referred to as exacerbations or attacks which are serious events - they can be fatal but at the very least have a major impact on patients' quality of life and considerable health economic consequences globally 3,. There remains significant unmet need in both asthma and copd.
Up to 20 of patients with asthma do not achieve an acceptable level of control, despite being prescribed high-dose anti-inflammatory and bronchodilator therapy, and are referred to as having difficult-to-treat asthma or difficult asthma 1,. In copd, even between exacerbations when patients are considered relatively stable, symptoms are still prevalent and problematic.
In a pan-European study of copd patients with severe disease (FEV1 50 predicted over 90 reported some degree of symptoms on a daily basis. While breathlessness was most typical, cough and sputum were also particularly bothersome.